A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome

A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome Publisher Pubmed

Kiaie N¹ ; Gorabi AM¹ ; Penson PE² ; Watts G³ ; Johnston TP⁴ ; Banach M^{5, 6} ; Sahebkar A^{7, 8, 9}

Show Affiliations

1. Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
2. School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom
3. Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, The University of Western Australia, Perth, WA, Australia
4. Division of Pharmacology and Pharmaceutical Science, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, United States
5. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, Poland
6. Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland
7. Halal Research Center of IRI, FDA, Tehran, Iran
8. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
9. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Drug Discovery Today Published:2020

Abstract

The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD. This review describes the experimental and clinical evidence for the use of liposomes in the diagnosis and management of atherosclerotic cardiovascular disease. © 2019 Elsevier Ltd

Related Docs

View other Related Docs

1. Potential Application of Liposomal Nanodevices for Non-Cancer Diseases: An Update on Design, Characterization and Biopharmaceutical Evaluation, Advances in Colloid and Interface Science (2020)

2. Nanotechnology in Diagnosis and Treatment of Coronary Artery Disease, Nanomedicine (2016)

3. The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis, Biomolecules (2019)

4. Validity of the Models Predicting 10-Year Risk of Cardiovascular Diseases in Asia: A Systematic Review and Prediction Model Metaanalysis, PLoS ONE (2023)

5. In Vitro Antioxidant Activity and in Vivo Wound-Healing Effect of Lecithin Liposomes: A Comparative Study, Journal of Comparative Effectiveness Research (2019)

6. Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol, Frontiers in Bioengineering and Biotechnology (2021)

7. Reduction of Doxorubicin-Induced Cardiotoxicity by Co-Administration of Smart Liposomal Doxorubicin and Free Quercetin: In Vitro and in Vivo Studies, Pharmaceutics (2023)

8. Peptide-Conjugated Liposomes for Targeted Mir-34A Delivery to Suppress Breast Cancer and Cancer Stem-Like Population, Journal of Drug Delivery Science and Technology (2020)

Experts (# of related papers)

View all Related Experts

Mehdi Yaseri (3)

Hossein Navid (2)

Style	Citing Format
MLA	Kiaie N, et al.. "A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome." Drug Discovery Today, vol. 25, no. 1, 2020, pp. 58-72.
APA	Kiaie N, Gorabi AM, Penson PE, Watts G, Johnston TP, Banach M, Sahebkar A (2020). A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome. Drug Discovery Today, 25(1), 58-72.
Chicago	Kiaie N, Gorabi AM, Penson PE, Watts G, Johnston TP, Banach M, Sahebkar A. "A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome." Drug Discovery Today 25, no. 1 (2020): 58-72.
Harvard	Kiaie N et al. (2020) 'A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome', Drug Discovery Today, 25(1), pp. 58-72.
Vancouver	Kiaie N, Gorabi AM, Penson PE, Watts G, Johnston TP, Banach M, et al.. A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome. Drug Discovery Today. 2020;25(1):58-72.
BibTex	@article{ author = {Kiaie N and Gorabi AM and Penson PE and Watts G and Johnston TP and Banach M and Sahebkar A}, title = {A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome}, journal = {Drug Discovery Today}, volume = {25}, number = {1}, pages = {58-72}, year = {2020} }
RIS	TY - JOUR AU - Kiaie N AU - Gorabi AM AU - Penson PE AU - Watts G AU - Johnston TP AU - Banach M AU - Sahebkar A TI - A New Approach to the Diagnosis and Treatment of Atherosclerosis: The Era of the Liposome JO - Drug Discovery Today VL - 25 IS - 1 SP - 58 EP - 72 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract